NCT00652626 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 14
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 45
- units
- Participants
- groups
- description
- Participants with normal renal function (defined as creatinine clearance \> 80 mL/min/1.73m\^2) received a single subcutaneous dose of azacitidine 25 mg/m\^2 on Day 1.
- id
- BG000
- title
- Azacitidine 25 mg/m^2
- description
- Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m\^2 on Day 1.
- id
- BG001
- title
- Azacitidine 50 mg/m^2
- description
- Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5.
- id
- BG002
- title
- Azacitidine 75 mg/m^2
- description
- Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m\^2 on Day 1.
- id
- BG003
- title
- Azacitidine 100 mg/m^2
- description
- Participants with severe renal impairment (RI; defined as creatinine clearance \< 30 mL/min/1.73 m\^2) received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5.
- id
- BG004
- title
- Severe RI: Azacitidine 75 mg/m^2
- description
- Participants with normal renal function (RF) received up to 6 cycles of treatment with 75 mg/m\^2 azacitidine daily on Days 1-7 of each 28-day cycle.
- id
- BG005
- title
- Extension Phase: Normal RF
- description
- Participants with severe renal impairment (RI) received up to 6 cycles of treatment with 75 mg/m\^2 azacitidine daily on Days 1-7 of each 28-day cycle.
- id
- BG006
- title
- Extension Phase: Severe RI
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 3.78
- value
- 67.6
- group Id
- BG001
- spread
- 9.63
- value
- 64.6
- group Id
- BG002
- spread
- 10.19
- value
- 53.5
- group Id
- BG003
- spread
- 12.02
- value
- 57.0
- group Id
- BG004
- spread
- 12.58
- value
- 74.5
- comment
- Data for provided initial treatment period arms only
- group Id
- BG005
- spread
- NA
- value
- NA
- comment
- Data provided for initial treatment period arms only
- group Id
- BG006
- spread
- NA
- value
- NA
- group Id
- BG007
- spread
- 12.32
- value
- 63.5
- title
- Initial Treatment Period
- categories
- measurements
- comment
- Data provided for extension treatment period arms only
- group Id
- BG000
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG001
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG002
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG003
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG004
- spread
- NA
- value
- NA
- group Id
- BG005
- spread
- 9.52
- value
- 60.6
- group Id
- BG006
- spread
- 11.0
- value
- 68.8
- group Id
- BG007
- spread
- 10.15
- value
- 62.4
- title
- Extension Treatment Period
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 16
- title
- Female
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 11
- title
- Male
- description
- Data provided for initial treatment phase groups only.
- param Type
- NUMBER
- title
- Sex/Gender, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 8
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 19
- title
- White
- description
- Data provided for initial treatment phase groups only.
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 27
- title
- United States
- description
- Data provided for initial treatment phase groups only.
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 10
- title
- Female
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 8
- title
- Male
- param Type
- NUMBER
- title
- Gender of Extension Period Participants
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 5
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 13
- title
- White
- param Type
- NUMBER
- title
- Race: Extension Phase
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 7
- title
- 0
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 18
- title
- 1
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- title
- 2
- description
- Scale used by doctors and researchers to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis. 0 = fully active, no restrictions; 1 = restricted but ambulatory and capable of light work; 2 = ambulatory and capable of self-care but unable to work. 3 = Capable of only limited self care, confined to bed or chair more than 50% of waking hours. 4 = Completely disabled. Cannot carry on any self care. Totally confined to bed or chair. 5 = Dead.
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status: Initial Treatment Phase
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 3
- title
- 0
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 14
- title
- 1
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- 2
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status: Extension Phase
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 0.20
- value
- 2.0
- group Id
- BG001
- spread
- 0.28
- value
- 1.9
- group Id
- BG002
- spread
- 0.42
- value
- 1.9
- group Id
- BG003
- spread
- 0.15
- value
- 1.6
- group Id
- BG004
- spread
- 0.15
- value
- 1.8
- comment
- Data provided for initial treatment period arms only
- group Id
- BG005
- spread
- NA
- value
- NA
- comment
- Data provided for initial treatment period arms only
- group Id
- BG006
- spread
- NA
- value
- NA
- group Id
- BG007
- spread
- 0.27
- value
- 1.9
- title
- Initial Treatment Period
- categories
- measurements
- comment
- Data provided for extension treatment period arms only
- group Id
- BG000
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG001
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG002
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG003
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG004
- spread
- NA
- value
- NA
- group Id
- BG005
- spread
- 0.35
- value
- 1.9
- group Id
- BG006
- spread
- 0.06
- value
- 1.9
- group Id
- BG007
- spread
- 0.31
- value
- 1.9
- title
- Extension Period
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Body Surface Area (BSA)
- unit Of Measure
- m^2
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- title
- Myelodysplastic syndrome-RA
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Myelodysplastic syndrome-RARS
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- title
- Myelodysplastic syndrome-RAEB-T
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Chronic myelomonocytic leukemia
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 20
- title
- Solid tumor
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Multiple myeloma
- description
- MDS = myelodysplastic syndrome; MM = multiple myeloma; RA = refractory anemia; RAEB-T = refractory anemia with excess blasts in transformation; RARS = refractory anemia with ringed sideroblasts; CMML = chronic myelomonocytic leukemia.
- param Type
- NUMBER
- title
- Cancer Diagnosis: Initial Treatment Phase
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- title
- Myelodysplastic syndrome-RA
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Myelodysplastic syndrome-RARS
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Myelodysplastic syndrome-RAEB-T
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Chronic myelomonocytic leukemia
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 12
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 15
- title
- Solid tumor
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Multiple myeloma
- param Type
- NUMBER
- title
- Cancer Diagnosis: Extension Phase
- unit Of Measure
- participants
- population Description
- Safety population. The total number of participants in the study was 27; 18 continued treatment in the extension phase.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 14
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 45
- units
- Participants
- groups
- description
- Participants with normal renal function (defined as creatinine clearance \> 80 mL/min/1.73m\^2) received a single subcutaneous dose of azacitidine 25 mg/m\^2 on Day 1.
- id
- BG000
- title
- Azacitidine 25 mg/m^2
- description
- Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m\^2 on Day 1.
- id
- BG001
- title
- Azacitidine 50 mg/m^2
- description
- Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5.
- id
- BG002
- title
- Azacitidine 75 mg/m^2
- description
- Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m\^2 on Day 1.
- id
- BG003
- title
- Azacitidine 100 mg/m^2
- description
- Participants with severe renal impairment (RI; defined as creatinine clearance \< 30 mL/min/1.73 m\^2) received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5.
- id
- BG004
- title
- Severe RI: Azacitidine 75 mg/m^2
- description
- Participants with normal renal function (RF) received up to 6 cycles of treatment with 75 mg/m\^2 azacitidine daily on Days 1-7 of each 28-day cycle.
- id
- BG005
- title
- Extension Phase: Normal RF
- description
- Participants with severe renal impairment (RI) received up to 6 cycles of treatment with 75 mg/m\^2 azacitidine daily on Days 1-7 of each 28-day cycle.
- id
- BG006
- title
- Extension Phase: Severe RI
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 3.78
- value
- 67.6
- group Id
- BG001
- spread
- 9.63
- value
- 64.6
- group Id
- BG002
- spread
- 10.19
- value
- 53.5
- group Id
- BG003
- spread
- 12.02
- value
- 57.0
- group Id
- BG004
- spread
- 12.58
- value
- 74.5
- comment
- Data for provided initial treatment period arms only
- group Id
- BG005
- spread
- NA
- value
- NA
- comment
- Data provided for initial treatment period arms only
- group Id
- BG006
- spread
- NA
- value
- NA
- group Id
- BG007
- spread
- 12.32
- value
- 63.5
- title
- Initial Treatment Period
- categories
- measurements
- comment
- Data provided for extension treatment period arms only
- group Id
- BG000
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG001
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG002
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG003
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG004
- spread
- NA
- value
- NA
- group Id
- BG005
- spread
- 9.52
- value
- 60.6
- group Id
- BG006
- spread
- 11.0
- value
- 68.8
- group Id
- BG007
- spread
- 10.15
- value
- 62.4
- title
- Extension Treatment Period
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 16
- title
- Female
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 11
- title
- Male
- description
- Data provided for initial treatment phase groups only.
- param Type
- NUMBER
- title
- Sex/Gender, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 8
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 19
- title
- White
- description
- Data provided for initial treatment phase groups only.
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 27
- title
- United States
- description
- Data provided for initial treatment phase groups only.
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 10
- title
- Female
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 8
- title
- Male
- param Type
- NUMBER
- title
- Gender of Extension Period Participants
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 5
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 13
- title
- White
- param Type
- NUMBER
- title
- Race: Extension Phase
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 7
- title
- 0
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 18
- title
- 1
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- title
- 2
- description
- Scale used by doctors and researchers to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis. 0 = fully active, no restrictions; 1 = restricted but ambulatory and capable of light work; 2 = ambulatory and capable of self-care but unable to work. 3 = Capable of only limited self care, confined to bed or chair more than 50% of waking hours. 4 = Completely disabled. Cannot carry on any self care. Totally confined to bed or chair. 5 = Dead.
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status: Initial Treatment Phase
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 3
- title
- 0
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 14
- title
- 1
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- 2
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status: Extension Phase
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 0.20
- value
- 2.0
- group Id
- BG001
- spread
- 0.28
- value
- 1.9
- group Id
- BG002
- spread
- 0.42
- value
- 1.9
- group Id
- BG003
- spread
- 0.15
- value
- 1.6
- group Id
- BG004
- spread
- 0.15
- value
- 1.8
- comment
- Data provided for initial treatment period arms only
- group Id
- BG005
- spread
- NA
- value
- NA
- comment
- Data provided for initial treatment period arms only
- group Id
- BG006
- spread
- NA
- value
- NA
- group Id
- BG007
- spread
- 0.27
- value
- 1.9
- title
- Initial Treatment Period
- categories
- measurements
- comment
- Data provided for extension treatment period arms only
- group Id
- BG000
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG001
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG002
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG003
- spread
- NA
- value
- NA
- comment
- Data provided for extension treatment period arms only
- group Id
- BG004
- spread
- NA
- value
- NA
- group Id
- BG005
- spread
- 0.35
- value
- 1.9
- group Id
- BG006
- spread
- 0.06
- value
- 1.9
- group Id
- BG007
- spread
- 0.31
- value
- 1.9
- title
- Extension Period
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Body Surface Area (BSA)
- unit Of Measure
- m^2
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- title
- Myelodysplastic syndrome-RA
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Myelodysplastic syndrome-RARS
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- title
- Myelodysplastic syndrome-RAEB-T
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Chronic myelomonocytic leukemia
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 20
- title
- Solid tumor
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Multiple myeloma
- description
- MDS = myelodysplastic syndrome; MM = multiple myeloma; RA = refractory anemia; RAEB-T = refractory anemia with excess blasts in transformation; RARS = refractory anemia with ringed sideroblasts; CMML = chronic myelomonocytic leukemia.
- param Type
- NUMBER
- title
- Cancer Diagnosis: Initial Treatment Phase
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- title
- Myelodysplastic syndrome-RA
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Myelodysplastic syndrome-RARS
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Myelodysplastic syndrome-RAEB-T
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Chronic myelomonocytic leukemia
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 12
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 15
- title
- Solid tumor
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Multiple myeloma
- param Type
- NUMBER
- title
- Cancer Diagnosis: Extension Phase
- unit Of Measure
- participants
- population Description
- Safety population. The total number of participants in the study was 27; 18 continued treatment in the extension phase.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle